menu
    • menu
    [{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vector Pharma \/ R-Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ R-Pharm"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Yale University","sponsor":"R-Pharm US","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ R-Pharm US","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ R-Pharm US"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Susan G. Komen for the Cure | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Susan G. Komen for the Cure | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Susan G. Komen for the Cure | Amgen Inc"},{"orgOrder":0,"company":"US Oncology Research","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"US Oncology Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"US Oncology Research \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"US Oncology Research \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Genentech | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Genentech | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Providence Health & Services \/ Genentech | Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals for Ixabepilone

    Menu

    Ixabepilone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vector Pharma

                            U.A.E arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vector Pharma

                            U.A.E arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : R-Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East

                            Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 22, 2021

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : R-Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

                            Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2021

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Ca...

                            Details : Allarity is currently conducting a DRP®-guided Phase 2 clinical trial to evaluate IXEMPRA® for the treatment of third-line metastatic breast cancer, with numerous trial sites planned in Europe, including Belgium, England, Denmark, Finland, Poland and G...

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2021

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $1.1 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD ...

                            Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 11, 2021

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $1.1 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $1.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD a...

                            Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 22, 2020

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $1.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Allarity Therapeutics

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $11.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Allarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD ...

                            Details : This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, steno...

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 05, 2020

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Negma Group

                            Deal Size : $11.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yale University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Yale University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : R-Pharm US

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

                            Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Ovarian Epithelial.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 28, 2017

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : R-Pharm US

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sidney Kimmel Cancer Center, Thomas Jefferson University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sidney Kimmel Cancer Center, Thomas Jefferson University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Susan G. Komen for the Cure | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic ...

                            Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2011

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Susan G. Komen for the Cure | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            US Oncology Research

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            US Oncology Research

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ixabepilone + Carboplatin Metastatic Breast Cancer

                            Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 24, 2010

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Providence Health & Services

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Providence Health & Services

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Genentech | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

                            Details : Ixabepilone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2010

                            Lead Product(s) : Ixabepilone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Genentech | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth